Tougher China Data Protection Laws Put Health Players On Alert
Some Tech Firms Already Exiting
Executive Summary
First LinkedIn, now Yahoo, the exodus of global tech giants from China indicates a toughening regulatory environment over personal data collection, storage and use with implications for pharma. Buckle up for a bumpy ride, experts say.
You may also be interested in...
Accenture Sees AI Solutions For IDMP Compliance, Trial Efficiency
AI could help companies comply with regulations like GDPR and IDMP, apart from optimizing clinical trial processes, Accenture’s managing director leading R&D analytics in North America says, as he lists cases where the firm drove cost savings.
Hard Decoupling: Foreign Firms Less Optimistic About China But Health Sector Revenues Growing
Latest US trade group business survey shows R&D-based pharma and medical device companies continue to see China as an important growth driver but amid unequal market access, ongoing regulatory concerns, and patchy IP protection improvements.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.